Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;19(4):221-234.
doi: 10.3909/riu0772.

The Use of Biomarkers in Prostate Cancer Screening and Treatment

Ashley V Alford  1 , Joseph M Brito  2 , Kamlesh K Yadav  3 , Shalini S Yadav  3 , Ashutosh K Tewari  3 , Joseph Renzulli  2
Affiliations
Review

The Use of Biomarkers in Prostate Cancer Screening and Treatment

Ashley V Alford et al. Rev Urol. 2017.

Abstract

Prostate cancer screening and diagnosis has been guided by prostate-specific antigen levels for the past 25 years, but with the most recent US Preventive Services Task Force screening recommendations, as well as concerns regarding overdiagnosis and overtreatment, a new wave of prostate cancer biomarkers has recently emerged. These assays allow the testing of urine, serum, or prostate tissue for molecular signs of prostate cancer, and provide information regarding both diagnosis and prognosis. In this review, we discuss 12 commercially available biomarker assays approved for the diagnosis and treatment of prostate cancer. The results of clinical validation studies and clinical decision-making studies are presented. This information is designed to assist urologists in making clinical decisions with respect to ordering and interpreting these tests for different patients. There are numerous fluid and biopsy-based genomic tests available for prostate cancer patients that provide the physician and patient with different information about risk of future disease and treatment outcomes. It is important that providers be able to recommend the appropriate test for each individual patient; this decision is based on tissue availability and prognostic information desired. Future studies will continue to emphasize the important role of genomic biomarkers in making individualized treatment decisions for prostate cancer patients.

Keywords: 4Kscore; Apifiny; Biomarkers; ConfirmMDx; Decipher; Michigan Prostate Score; PCA3; PTEN/TMPRSS2:ERG; ProMark; Prolaris; Prostate Health Index; Prostate cancer; SelectMDx.

PubMed Disclaimer

References

    1. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society Prostate Cancer Advisory Committee American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70–98. - PubMed
    1. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev. 2001;23:181–186. - PubMed
    1. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993;269:2633–2636. - PubMed
    1. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046–1055. - PMC - PubMed
    1. Andriole GL, Crawford ED, Grubb RL, et al. PLCO Project Team Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319. - PMC - PubMed

LinkOut - more resources